Deutsche Bank Keeps 'Hold' on Biosite

Analyst Bruce Jacobs says he's concerned about the lack of visibility on Biosite's blood-test business

Deutsche Bank keeps hold on Biosite (BSTE ), and cut the price target to $33.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.